BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32800323)

  • 1. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
    He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
    Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis.
    He Y; Wang T; Li N; Yang B; Hu Y
    Medicine (Baltimore); 2020 Feb; 99(8):e19281. PubMed ID: 32080141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
    Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
    Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
    Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
    PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
    Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
    Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
    Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
    Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
    Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
    Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
    Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
    Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
    Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
    Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of POLE proofreading mutations in endometrial cancer.
    Church DN; Stelloo E; Nout RA; Valtcheva N; Depreeuw J; ter Haar N; Noske A; Amant F; Tomlinson IP; Wild PJ; Lambrechts D; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Creutzberg CL; Bosse T
    J Natl Cancer Inst; 2015 Jan; 107(1):402. PubMed ID: 25505230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
    McConechy MK; Talhouk A; Leung S; Chiu D; Yang W; Senz J; Reha-Krantz LJ; Lee CH; Huntsman DG; Gilks CB; McAlpine JN
    Clin Cancer Res; 2016 Jun; 22(12):2865-73. PubMed ID: 26763250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
    Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of a droplet digital PCR assay for detecting
    Kim G; Lee SK; Suh DH; Kim K; No JH; Kim YB; Kim H
    J Gynecol Oncol; 2022 Mar; 33(2):e15. PubMed ID: 34910396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups.
    Rau TT; Bettschen E; Büchi C; Christe L; Rohner A; Müller MD; Carlson JW; Imboden S; Zlobec I
    Mod Pathol; 2021 Jan; 34(1):222-232. PubMed ID: 32728223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
    Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
    Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
    Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
    Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
    Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
    Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.